Trials / Completed
CompletedNCT05961280
Selective Omission of Sentinel Lymph Node Biopsy in Mastectomy for Ductal Carcinoma in Situ: Identifying Eligible Candidates
Upstaging and Lymph Node Metastasis Rate in Patients With Ductal Carcinoma in Situ Who Received Mastectomy Regarding the Necessary of Sentinel Lymph Node Biopsy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 385 (actual)
- Sponsor
- Gangnam Severance Hospital · Academic / Other
- Sex
- Female
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to assess the prevalence of upgrade to invasive breast cancer and axillary lymph node metastasis in patients who were diagnosed with DCIS on biopsy and subsequently underwent mastectomy with axillary surgery to establish the need for SLNB. Furthermore, we explored the clinicopathologic features related to the upgrade to invasive breast cancer and axillary lymph node metastasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Mastectomy with sentinel lymph node biopsy |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2021-12-30
- Completion
- 2021-12-30
- First posted
- 2023-07-27
- Last updated
- 2023-07-27
Source: ClinicalTrials.gov record NCT05961280. Inclusion in this directory is not an endorsement.